OVERVIEW ·     TRACK
RECORD		 ·     BENEFITS ·     FAQs  ·    WHAT'S NEXT ·      HOW WE
PICK STOCKS		 ·       SUBSCRIBE ·      PENNYSTOCKSTM
NEWSLETTER  

Forbes Directory - Best of the Web
Best of the Web
(Small Caps)
Barron's > read review
As Featured:
*BARRON's
*CNNfn.com
*BusinessWeek Online
*Wired News
*C/NET
*Barron's Electronic
Edition

*Home
*Links
*Sitemap

The only penny stock site recommended in Barron's and by Forbes.

Online since 1996, we pick stocks trading at under $5.00 that are listed on the NYSE, NASDAQ, and AMEX.

To learn what this site is really about, we urge you to visit the Overview and Track Record pages. However, before doing so, take a glance at a few of our all-time winners. Of course, these are the subsequent gains reached once they hit our target prices and we closed the positions, but it is fun to ponder. The first price was the initial recommendation, followed by the subsequent high, and the eventual ultimate percentage gain. No doubt, you will recognize most of these companies.

Netegrity $2.18 to $73.20 3487%
(acquired by IBM)
Inhibitex $2.35 to $24.08 925%
(acquired by BristolMyersSquibb)
Cellstar $1.44 to $13.50 837%
Iomega $3.25 to $13.90 328%
Nanophase $3.75 to $16.75 347%
Immunomedics $1.44 to $29.12 1922%
Total Renal Care $3.12 to $26.95 741%
Voxware $ .90 to $10.31 1046%
Corvas $3.00 to $23.25 675%
Cytogen $2.12 to $17.50 725%
Verilink $3.00 to $14.62 387%
GeneLabs $2.31 to $10.72 364%
70% FOR GAINS!
70% OF OUR CLOSED POSITIONS
ARE FOR GAINS OF 50%
OR GREATER (see TRACK RECORD)
RIGHT NOW!
IN THE CURRENT NEWSLETTER!

NOTE: This is our second go-around with these picks; the first time with both of them worked very well, as have many of our other second timers:

THREE ANALYSTS rate this biotech a BUY as it is developing nearly a dozen products to treat various forms of cancer; trading near its yearly low at around $1.15 a share.

And THREE ANALYSTS rate this biotech a STRONG BUY as it develops therapies for neurological disorders such as Parkinson's disease; trading near its 52-week low at around $2.10 a share.

Hold on for the wild rides!
See "What's Next"
Disclaimer: Penny stock trading involves substantial risk, so always research every recommendation before trading, consult with licensed professionals before trading, and always trade with caution. The recommendations listed in the Newsletter are only for investment ideas and are not solicitations to purchase equities. For more extensive details, view the Privacy Policy and Disclaimer page.


Copyright ®1996-2013 Global Penny Stocks®
Site created by Princeton Internet Group, Inc. (PING)
Privacy Policy and Disclaimer